Clinical Trials
42 trialsWeight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma
Fudan University
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
University of Oklahoma
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
M.D. Anderson Cancer Center
Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP
Fudan University
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
Virginia Commonwealth University
CAN-STAMP
University Health Network, Toronto
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
University of Maryland, Baltimore
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Dana-Farber Cancer Institute
SCC-BAREDU
University of Oklahoma
Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
Stanford University
Study of Copanlisib and Ketogenic Diet
Columbia University
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
Ohio State University Comprehensive Cancer Center
Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
Fox Chase Cancer Center
Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer
Wake Forest University Health Sciences
Evaluation of Outcomes in Women Undergoing Multimodality Treatment for Advanced Stage Endometrial Carcinoma
Henry Ford Health System
Comparison of Nodal Staging in Endometrial Cancer
University of Kentucky
Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer
UNC Lineberger Comprehensive Cancer Center
MA-EEC
Sunnybrook Health Sciences Centre
Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer
Stanford University
NR in Chemo-induced Peripheral Neuropathy
University of Iowa
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
Vanderbilt-Ingram Cancer Center
Vire-Brachy
Centre Hospitalier Universitaire de Saint Etienne
Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
University of Chicago
Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery
Case Comprehensive Cancer Center
Evaluating the Effect of Perioperative Caloric Restriction Program on Perioperative Outcomes in Patients With Obesity and Endometrial Cancer
Abramson Cancer Center at Penn Medicine
The Role of Hypoxia as a Selective Pressure for TP53 Mutations
Institute of Cancer Research, United Kingdom
Chemoradiation-Induced Nausea and Emesis: Quality of Life
M.D. Anderson Cancer Center
STATEC
University College, London
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
Mayo Clinic
N1
CureOne
Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium
University of California, San Diego
Efficacy of PET/MRI in Detecting Metastatic Disease in Endometrial Cancer
Mayo Clinic
Racial Disparity in Endometrial Cancer
University of Louisville
TOMOGYN
Centre Oscar Lambret
NRR
UNC Lineberger Comprehensive Cancer Center
Hysteroscopic Lymphatic Mapping for Endometrial Cancer
M.D. Anderson Cancer Center
Psychosocial Benefits of Exercise in Endometrial Cancer Survivors
University of Alabama at Birmingham
Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer
Roswell Park Cancer Institute
Sleep and Endometrial Cancer
University of Pittsburgh
A Randomized, Controlled, Comparative Study of a Levonorgestrel Intrauterine System for the Prevention of Endometrial Cancer in Patients Aged 40-50 With BMI Greater Than 35
Rutgers, The State University of New Jersey